Anaplastic Thyroid Cancer: A report of 5 consecutive cases treated successfully with nab-Paclitaxel.

At the beginning of June 2015, the Annual Meeting of the American Society of Clinical Oncology (ASCO) took place in Chicago. A total of 24 studies in the field of thyroid oncology were presented, being discussed in the present review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. Kinase inhibitors are used primarily in the context of palliative treatment concepts. The most recent treatment options in thyroid oncology, both surgical and medical, are summarized in the following article.

show abstract

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Lőrincz

Topp

Knecht

2015

HNO

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Anaplastic Thyroid Cancer: A report of 5 consecutive cases treated successfully with nab-Paclitaxel.

Cited by 1 publication

References 0 publications

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Neue Aspekte in der Therapie von Schilddrüsenkarzinomen

Contact Info

Product

Resources

About